Articles tagged with Psychopharmacology
A study reveals that nearly one-third of ADHD-diagnosed foster care youth aged 2-17 received atypical antipsychotics, highlighting a critical trend in pediatric psychiatry. The most common medications given were risperidone, aripiprazole, and quetiapine.
Scientists Jürgen Rehm and David Nutt propose a simple 10-point plan to reduce personal and public costs of alcohol. The plan includes monitoring individual intake, limiting consumption, taking breaks from drinking, and implementing government interventions such as minimum pricing, labeling, and treatment.
The British Association for Psychopharmacology has released updated guidelines for treating substance abuse and addiction, focusing on pharmacological management. The new guidelines provide a comprehensive review of evidence-based practices for practitioners to optimize clinical decisions.
More than 2 million US teenagers suffer from depression, with few receiving adequate treatment. New research highlights the need for more effective treatments and better therapeutic strategies.
Researchers found that higher concentrations of 1,8-cineole in the blood correlate with improved cognitive performance, including speed and accuracy tests. Positive mood also showed a significant relationship with 1,8-cineole levels, proposing that contentedness may improve performance.
A special issue of Journal of Child and Adolescent Psychopharmacology explores new treatments for pediatric-onset OCD and Tourette's disorder, including riluzole, a drug approved for ALS that shows promise in psychiatric conditions. Researchers propose identifying specific brain circuits as targets for new drug development.
The British Association for Psychopharmacology has released new guidelines to guide psychiatrists and physicians in treating sleep disorders. These guidelines recommend cognitive behavioral therapy as an effective treatment option for insomnia, which can be improved with specialist targeted therapy. The guidelines also address specific...
A study published in Journal of Psychopharmacology found that MDMA, a pharmaceutical version of Ecstasy, can enhance the effectiveness of exposure therapy for PTSD. By increasing oxytocin levels and reducing fear responses, ecstasy may help patients overcome traumatic memories and reduce stress.
Researchers at Johns Hopkins Medicine have found that the spiritual effects of psilocybin, a hallucinogen, can last more than a year. Most volunteer subjects reported the experience as one of the most personally meaningful and spiritually significant events of their lives.
New British Association of Pharmacology guidelines suggest that antidepressants are effective in treating depression, especially severe cases. In contrast, evidence for cognitive behavioural therapy (CBT) is limited, particularly for mild and moderate depression.
Experts warn that psychotherapies like CBT can have serious adverse effects, including worsening of conditions, psychological dependency, and exploitation. They call for rigorous regulation and monitoring to ensure patient safety and effectiveness.
Research explores alternative models for reducing alcohol consumption, including tax incentives and low-alcohol drinks. Pharmacological investigation into safe substitutes like partial agonists could hold the key to eradicating alcohol misuse problems.
A recent study found that daily smokers experience impaired time estimation when abstaining from cigarettes for 24 hours. This impairment may contribute to feelings of stress and decreased focus, highlighting the need for further research on nicotine's effects on attention processes.